Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||15%|
|1 Day Vol Adjusted Return||0.9|
|1 Month Vol Adjusted Return||1.6|
|3 Month Vol Adjusted Return||-1.0|
|6 Month Vol Adjusted Return||-0.9|
|20 Days SMA Price ZScore||1.3|
|50 Days SMA Price ZScore||-0.1|
|12 -26 Days PPO||-3.1|
|1 Month Average Short Volume Ratio||24.7|
|1 Day Volume Change ZScore||0.1|
|1 Month Daily Vol||5.8|
RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 Nyxol has the Potential Opportunity to Address Estimated $500M+ Reversal of Dilation Market with No Approved Therapies Today FARMINGTON HILLS, Mich., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Expected in Early 2022 for Nyxol in Night Vision Disturbance, RM, and RM for Pediatric Patients Planned NDA Submission for Nyxol in Reversal of Mydriasis Indication in Late 2022 More Publications Supporting Novel Transcription Factor (Ref-1) Inhibitor, APX3330, Targeting Both Neovascularization and Inflammation in Ret
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative Therapies for Retinal Disease and Presbyopia FARMINGTON HILLS, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today an
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macular Degeneration Ocuphire’s Phase 2 ZETA-1Trial Evaluating APX3330 (an Oral Ref-1 Inhibitor) for the Treatment of Diabetic Retinopathy is Currently Recruiting with Data Expected in 2022 FARMINGTON HILLS, Mich., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stag